<DOC>
	<DOC>NCT02914509</DOC>
	<brief_summary>To evaluate the safety and IOP lowering efficacy of OTX-TP, a sustained release travoprost drug product, placed in the canaliculus of the eyelid in the treatment of subjects with open-angle glaucoma or ocular hypertension.</brief_summary>
	<brief_title>Study Evaluating OTX-TP in OAG and OH</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma, Open-Angle</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Travoprost</mesh_term>
	<criteria>Documented diagnosis of ocular hypertension with an open angle of Schaffer Grade 3 or greater or openangle glaucoma without pseudoexfoliation or pigment dispersion or evidence of traumatic angle recession. Punctum size smaller than 0.4 mm or greater than 0.9 mm in either eye as measured using a standard punctum gauge. Known or suspected allergy and/or hypersensitivity to Travoprost or any prostaglandin, fluorescein, or to any component of the study products.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>